

# Resource Summary Report

Generated by [dkNET](#) on Apr 23, 2025

## Bioreclamation

RRID:SCR\_004728

Type: Tool

### Proper Citation

Bioreclamation (RRID:SCR\_004728)

### Resource Information

**URL:** <http://www.bioreclamationivt.com/>

**Proper Citation:** Bioreclamation (RRID:SCR\_004728)

**Description:** BioIVT, formerly BioreclamationIVT, is global provider of biological specimens and services. Provides biological and in vitro products specializing in control and disease state matrices manufactured from human and animal whole blood, plasma, serum, tissues and other fluids which are used in drug discovery, compound development, clinical and research diagnostics.

**Synonyms:** BioreclamationIVT - The complete resource for all biologicals, BioreclamationIVT

**Resource Type:** commercial organization

**Keywords:** immunology, biological, clinical, matrix, disease state matrix, control matrix, hepatocyte, cell, subcellular fraction, cell culture, blood, fluid, tissue, renal cell, media, renal proximal tubule cell, in vitro cyp microsome

**Funding:**

**Resource Name:** Bioreclamation

**Resource ID:** SCR\_004728

**Alternate IDs:** nlx\_72707

**Alternate URLs:** <http://www.bioreclamation.com/>, <https://bioivt.com/>

**Record Creation Time:** 20220129T080226+0000

**Record Last Update:** 20250420T014234+0000

---

## Ratings and Alerts

No rating or validation information has been found for Bioreclamation.

No alerts have been found for Bioreclamation.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 274 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#).

Milani N, et al. (2024) In silico modeling and simulation of organ-on-a-chip systems to support data analysis and a priori experimental design. *CPT: pharmacometrics & systems pharmacology*, 13(4), 524.

Blauvelt A, et al. (2024) Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy. *JID innovations : skin science from molecules to population health*, 4(5), 100287.

Govendir M, et al. (2024) Pharmacokinetic profile of oral and subcutaneous administration of paracetamol in the koala (*Phascolarctos cinereus*) and prediction of its analgesic efficacy. *PloS one*, 19(4), e0300703.

Hong KU, et al. (2024) Investigation on regulation of N-acetyltransferase 2 expression by nuclear receptors in human hepatocytes. *Frontiers in pharmacology*, 15, 1488367.

Skidmore LK, et al. (2024) Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer. *Molecular cancer therapeutics*, 23(12), 1842.

Liu Y, et al. (2024) Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses. *Emerging microbes & infections*, 13(1), 2350167.

Torta F, et al. (2024) Concordant inter-laboratory derived concentrations of ceramides in human plasma reference materials via authentic standards. *Nature communications*, 15(1), 8562.

DiCesare SM, et al. (2024) GSK3 inhibition reduces ECM production and prevents age-related macular degeneration-like pathology. *JCI insight*, 9(15).

Vanarsa K, et al. (2023) Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging. *BMC medicine*, 21(1), 133.

Mesman AW, et al. (2023) Detection of *Mycobacterium tuberculosis* transrenal DNA in urine samples among adult patients in Peru. *medRxiv : the preprint server for health sciences*.

Li X, et al. (2023) Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. *Molecular cancer therapeutics*, 22(2), 155.

Kolodziejek AM, et al. (2023) *Yersinia pestis* ?ail Mutants Are Not Susceptible to Human Complement Bactericidal Activity in the Flea. *Applied and environmental microbiology*, 89(2), e0124422.

DiCesare SM, et al. (2023) GSK3 inhibition reduces ECM production and prevents age-related macular degeneration-like pathology. *bioRxiv : the preprint server for biology*.

Campbell K, et al. (2023) Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab. *ImmunoHorizons*, 7(4), 273.

Kuzmichev YV, et al. (2023) Application of ultrasensitive digital ELISA for p24 enables improved evaluation of HIV-1 reservoir diversity and growth kinetics in viral outgrowth assays. *Scientific reports*, 13(1), 10958.

Chen YL, et al. (2023) Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans. *Neurology and therapy*, 12(3), 815.

Liu X, et al. (2022) Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. *Nature cancer*, 3(7), 866.

Zetterberg FR, et al. (2022) Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease. *Journal of medicinal chemistry*, 65(19), 12626.

Dicker I, et al. (2022) GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile. *Antimicrobial agents and chemotherapy*, 66(1), e0187621.

Ramsden D, et al. (2022) Characterization of Correction Factors to Enable Assessment of Clinical Risk from In Vitro CYP3A4 Induction Data and Basic Drug-Drug Interaction Models. *European journal of drug metabolism and pharmacokinetics*, 47(4), 467.